Transglutaminase-2 Cross-Linking Inhibition Strategy

Target: TGM2 Composite Score: 0.639 Price: $0.64▲54.2% Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
9
Citations
3
Debates
3
Supporting
3
Opposing
Quality Report Card click to collapse
B
Composite: 0.639
Top 39% of 1510 hypotheses
T1 Established
Multi-source converged and validated
T0 Axiom requires manual override only
B+ Mech. Plausibility 15% 0.75 Top 29%
B Evidence Strength 15% 0.60 Top 44%
B+ Novelty 12% 0.70 Top 45%
A Feasibility 12% 0.80 Top 22%
B+ Impact 12% 0.70 Top 45%
A Druggability 10% 0.85 Top 21%
B Safety Profile 8% 0.65 Top 30%
B+ Competition 6% 0.75 Top 31%
B+ Data Availability 5% 0.70 Top 35%
B+ Reproducibility 5% 0.75 Top 18%
Evidence
3 supporting | 3 opposing
Citation quality: 85%
Debates
1 session A+
Avg quality: 0.95
Convergence
1.00 A+ 30 related hypothesis share this target

From Analysis:

Protein aggregation cross-seeding across neurodegenerative diseases

What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?

→ View full analysis & debate transcript

Description

Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"] B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"] B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"] B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"] B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"] C --> G["Neurofibrillary
Tangle Formation"] D --> H["Amyloid Plaque
Stabilization"] E --> I["Peripheral Immune
Cell Infiltration"] F --> J["Chronic
Neuroinflammation"] G --> K["Neuronal Death
& Cognitive Decline"] H --> K I --> J J --> K L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"] M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"] M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"] M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"] M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"] N --> R["Neuroprotection &
Cognitive Preservation"] O --> R P --> R Q --> R style A fill:#ff8a80,stroke:#d32f2f,color:#000 style L fill:#4fc3f7,stroke:#2196f3,color:#000 style R fill:#81c784,stroke:#4caf50,color:#000 style K fill:#ffab91,stroke:#e64a19,color:#000

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.75 (15%) Evidence 0.60 (15%) Novelty 0.70 (12%) Feasibility 0.80 (12%) Impact 0.70 (12%) Druggability 0.85 (10%) Safety 0.65 (8%) Competition 0.75 (6%) Data Avail. 0.70 (5%) Reproducible 0.75 (5%) KG Connect 0.74 (8%) 0.639 composite
6 citations 6 with PMID Validation: 85% 3 supporting / 3 opposing
For (3)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
MECH 6CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Transglutaminase-2 cross-links tau, α-synuclein, a…SupportingMECH----PMID:25242045-
TG2 activity is elevated in multiple neurodegenera…SupportingMECH----PMID:27784544-
Selective TG2 inhibitors reduce protein aggregatio…SupportingMECH----PMID:31756126-
TG2 activity can be protective in some neurodegene…OpposingMECH----PMID:27784544-
TG2 cross-linking often occurs after aggregate for…OpposingMECH----PMID:25242045-
Non-selective TG2 inhibition causes significant to…OpposingMECH----PMID:28847752-
Legacy Card View — expandable citation cards

Supporting Evidence 3

Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions
TG2 activity is elevated in multiple neurodegenerative diseases
Selective TG2 inhibitors reduce protein aggregation

Opposing Evidence 3

TG2 activity can be protective in some neurodegeneration contexts
TG2 cross-linking often occurs after aggregate formation, not during initial seeding
Non-selective TG2 inhibition causes significant toxicity
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration

Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor

Description: DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.

Target: DNAJB6 (DnaJ heat shock protein family member B6)

Supporting Evidence: DNAJB6 pote

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Specific Weaknesses:

  • The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
  • No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
  • The cited PMIDs don't actually support cross-seeding inhibition claims
Counter-evidence:
  • DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

PRACTICAL FEASIBILITY ASSESSMENT

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Druggability: MODERATE-POOR

  • Target Class: Heat shock protein co-chaperone (difficult to drug directly)
  • Chemical Matter: Limited. No known direct DNAJB6 activators exist
  • Existing Tools:
  • HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
  • Gene therapy vectors for DNAJB6 overexpression (preclinical only)
Competitive Landscape:
  • Direct competitors: None targeting DNAJB6 specifically
  • Adjacent space: Multiple HSP70/HSP90 programs (Orphazy

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.250.500.75 created: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:43)score_update: market_dynamics (2026-04-02T23:19)debate: market_dynamics (2026-04-02T23:20)evidence: evidence_batch_update (2026-04-03T01:06)evidence: evidence_batch_update (2026-04-03T01:06)evidence: market_dynamics (2026-04-03T02:14)debate: market_dynamics (2026-04-03T03:00)evidence: market_dynamics (2026-04-03T03:10)debate: market_dynamics (2026-04-03T04:44)score_update: market_dynamics (2026-04-03T08:00)evidence: market_dynamics (2026-04-03T08:14)debate: market_dynamics (2026-04-03T09:14)evidence: evidence_batch_update (2026-04-04T09:08)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 1.00 0.00 2026-04-022026-04-122026-04-22 Market PriceScoreevidencedebate 159 events
7d Trend
Stable
7d Momentum
▼ 1.3%
Volatility
Medium
0.0345
Events (7d)
6
⚡ Price Movement Log Recent 15 events
Event Price Change Source Time
📄 New Evidence $0.516 ▲ 1.8% evidence_batch_update 2026-04-13 02:18
📄 New Evidence $0.507 ▲ 3.9% evidence_batch_update 2026-04-13 02:18
Recalibrated $0.488 ▼ 1.2% 2026-04-10 15:58
Recalibrated $0.494 ▲ 1.4% 2026-04-10 15:53
Recalibrated $0.487 ▲ 0.3% 2026-04-08 18:39
Recalibrated $0.486 ▼ 0.7% 2026-04-04 16:38
Recalibrated $0.489 ▼ 1.9% 2026-04-04 16:02
📄 New Evidence $0.499 ▲ 2.2% evidence_batch_update 2026-04-04 09:08
Recalibrated $0.488 ▼ 27.6% 2026-04-03 23:46
💬 Debate Round $0.674 ▲ 2.0% market_dynamics 2026-04-03 09:14
📄 New Evidence $0.661 ▼ 1.8% market_dynamics 2026-04-03 08:14
📊 Score Update $0.673 ▲ 24.1% market_dynamics 2026-04-03 08:00
💬 Debate Round $0.542 ▼ 4.2% market_dynamics 2026-04-03 04:44
📄 New Evidence $0.566 ▼ 11.0% market_dynamics 2026-04-03 03:10
💬 Debate Round $0.636 ▲ 25.8% market_dynamics 2026-04-03 03:00

Clinical Trials (4) Relevance: 13%

2
Active
2
Completed
0
Total Enrolled
Phase II/III
Highest Phase
Cysteamine Bitartrate in Huntington's Disease (CYST-HD) Phase II/III
Completed · NCT02101957
Cysteamine for Neurodegenerative Disease Phase II
Completed · NCT03344601
Zampilimab (anti-TG2) in Celiac Disease Phase II
Recruiting · NCT04870866
Cross-Seeding Biomarkers in Neurodegenerative Disease Observational
Recruiting · NCT05538455

📚 Cited Papers (23)

[WALANT - Wide Awake Local Anaesthesia No Tourniquet: Complications in elective and acute traumatological Hand Surgery Procedures].
Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... (2022) · PMID:35168268
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
Engineering complex communities by directed evolution.
Nature ecology & evolution (2021) · PMID:33986540
9 figures
Extended Data Figure 1.
Extended Data Figure 1.
Non-additive function, costly function, and two empirically motivated functions. (A) Illustration of the different types of community function we have considered. In addition to th...
pmc_api
Extended Data Figure 2.
Extended Data Figure 2.
Alternative ecological scenarios with metabolic cross-feeding. Besides the rich medium without cross-feeding shown in the main text, we have included two other ecological scenarios...
pmc_api
Dietary Gluten and Neurodegeneration: A Case for Preclinical Studies.
International journal of molecular sciences (2020) · PMID:32751379
3 figures
Figure 1
Figure 1
Occludin (OCLN) protein expression is significantly decreased in duodenal epithelium of celiac macaques. All panels involve triple labels with OCLN ( green ), cytokeratin ( red ) a...
pmc_api
Figure 2
Figure 2
Immunopathology of central nervous system (CNS) disease in celiac disease patients and potential beneficial (treatment) role of phytocannabinoids as nutraceuticals to mitigate glut...
pmc_api
TGM2 and implications for human disease: role of alternative splicing.
Front Biosci (Landmark Ed) (2013) · PMID:23276939
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.
International journal of molecular sciences (2024) · PMID:39769187
4 figures
Figure 1
Figure 1
Toxic protein biomarkers shared by specific and mixed pathology NDDs. The references supporting these relationships are cited in the main body of the text. The color of the individ...
pmc_api
Figure 2
Figure 2
Calcium–calmodulin mediated signal transduction in normal neurons ( top panel ) and neurodegeneration ( lower panel ). This essential signaling pathway mediates learning and memory...
pmc_api
4 figures
Fig. 1.
Fig. 1.
Sonographic image of OCD of the humeral capitellum in the sagittal plane showing irregularity and discontinuity of the subchondral bone.
pmc_api
Fig. 2.
Fig. 2.
(A) Radiograph taken at the first examination showing an osteochondral lesion on the lateral side of the capitellum and new bone formation along the lateral side of capitellum (arr...
pmc_api
TGM2 and implications for human disease: role of alternative splicing.
Front Biosci (Landmark Ed) (2013) · PMID:23276939
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
Sounds interesting: can sonification help us design new proteins?
Expert review of proteomics (2020) · PMID:31756126
No extracted figures yet
No extracted figures yet

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score
0.80
56.0th percentile (747 hypotheses)
Tokens Used
5,377
KG Edges Generated
808
Citations Produced
9

Cost Ratios

Cost per KG Edge
122.20 tokens
Lower is better (baseline: 2000)
Cost per Citation
336.06 tokens
Lower is better (baseline: 1000)
Cost per Score Point
8297.84 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.080
10% weight of efficiency score
Adjusted Composite
0.719

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date Signal Price Score
2026-04-17T09:10$0.6280.552

Wiki Pages

EEDgeneTGM2 — Transglutaminase 2geneAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_toolTGM2 ProteinproteinTGM2 — Transglutaminase 2geneNeurodegenerationdiseaseAmyotrophic Lateral SclerosisredirectTau OligomersentityGenesindexEndoplasmic Reticulum Stress and Unfolded Protein mechanismBlood-Brain BarriercellParkinson's DiseasediseaseAmyotrophic Lateral Sclerosis (ALS)diseaseAlzheimer's DiseasediseaseDopaminergic Neuronscell

KG Entities (39)

DNAJB6DNAJB6_proteinG3BP1HSPA8HSPG2PHB2RNA_bindingRNA_splicingTDP-43TGM2TREM2TREM2_proteinalpha-synucleinalzheimers_diseaseamyloid_formationamyloid_nucleationautophagybeta_sheet_structurecross_seedingfrontotemporal_dementia

Dependency Graph (1 upstream, 0 downstream)

Depends On
Low Complexity Domain Cross-Linking Inhibitionrefines (0.5)

Related Hypotheses

Low Complexity Domain Cross-Linking Inhibition
Score: 0.617 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.921 | neurodegeneration
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.920 | neurodegeneration
HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM Transition
Score: 0.919 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
2.0 years

🧪 Falsifiable Predictions (3)

3 total 0 confirmed 0 falsified
If hypothesis is true, intervention be most beneficial, positioning this strategy for prodromal or mild cognitive impairment stages rather than established dementia
pending conf: 0.60
Expected outcome: be most beneficial, positioning this strategy for prodromal or mild cognitive impairment stages rather than established dementia
Falsified by: Intervention fails to be most beneficial, positioning this strategy for prodromal or mild cognitive impairment stages rather than established dementia
If hypothesis is true, intervention enable non-invasive monitoring of enzyme activity in living brains
pending conf: 0.60
Expected outcome: enable non-invasive monitoring of enzyme activity in living brains
Falsified by: Intervention fails to enable non-invasive monitoring of enzyme activity in living brains
If hypothesis is true, intervention provide non-invasive measures of enzyme activity and inhibitor penetration
pending conf: 0.60
Expected outcome: provide non-invasive measures of enzyme activity and inhibitor penetration
Falsified by: Intervention fails to provide non-invasive measures of enzyme activity and inhibitor penetration

Knowledge Subgraph (61 edges)

associated with (11)

taualzheimers_diseasealpha-synucleinparkinsons_diseaseTDP-43frontotemporal_dementiataufrontotemporal_dementiaalpha-synucleinlewy_body_dementia
▸ Show 6 more

binds (3)

DNAJB6_proteintauDNAJB6_proteinalpha-synucleinDNAJB6_proteinTDP-43

causes (2)

cross_seedingneurodegenerationprotein_misfoldingcross_seeding

cross-links (3)

transglutaminase-2tautransglutaminase-2alpha-synucleintransglutaminase-2TDP-43

cross-seeds (5)

taualpha-synucleinalpha-synucleintauTDP-43tauTDP-43alpha-synucleintauTDP-43

encodes (5)

TGM2transglutaminase-2HSPG2heparan_sulfate_proteoglycanTREM2TREM2_proteinDNAJB6DNAJB6_proteinPHB2prohibitin-2

inhibits (5)

TREM2_proteinprotein_aggregationmicrogliacross_seedingDNAJB6_proteinamyloid_formationubiquitin_proteasome_systemprotein_aggregationautophagyprotein_aggregation

interacts with (1)

HSPA8DNAJB6_protein

localizes to (5)

G3BP1stress_granulePHB2mitochondriaalpha-synucleinsynapsetausynapseprohibitin-2mitochondria

modulates (1)

TDP-43RNA_splicing

promotes (8)

G3BP1alpha-synucleinstress_granuleprotein_aggregationtransglutaminase-2protein_aggregationtransglutaminase-2cross_seedingheparan_sulfateamyloid_nucleation
▸ Show 3 more

recruits (6)

G3BP1TDP-43stress_granuleTDP-43stress_granuletaustress_granulealpha-synucleinPHB2TDP-43
▸ Show 1 more

regulates (2)

TDP-43RNA_bindingTDP-43stress_granule_assembly

scaffolds (2)

TDP-43stress_granuleTDP-43PHB2

templates (2)

heparan_sulfate_proteoglycantauheparan_sulfate_proteoglycanalpha-synuclein

Mechanism Pathway for TGM2

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    tau["tau"] -->|cross-seeds| alpha_synuclein["alpha-synuclein"]
    alpha_synuclein_1["alpha-synuclein"] -->|cross-seeds| tau_2["tau"]
    TDP_43["TDP-43"] -->|cross-seeds| tau_3["tau"]
    TDP_43_4["TDP-43"] -->|cross-seeds| alpha_synuclein_5["alpha-synuclein"]
    tau_6["tau"] -->|cross-seeds| TDP_43_7["TDP-43"]
    tau_8["tau"] -->|associated with| alzheimers_disease["alzheimers_disease"]
    alpha_synuclein_9["alpha-synuclein"] -->|associated with| parkinsons_disease["parkinsons_disease"]
    TDP_43_10["TDP-43"] -->|associated with| frontotemporal_dementia["frontotemporal_dementia"]
    tau_11["tau"] -->|associated with| frontotemporal_dementia_12["frontotemporal_dementia"]
    alpha_synuclein_13["alpha-synuclein"] -->|associated with| lewy_body_dementia["lewy_body_dementia"]
    cross_seeding["cross_seeding"] -->|associated with| multiple_system_atrophy["multiple_system_atrophy"]
    TGM2["TGM2"] -->|encodes| transglutaminase_2["transglutaminase-2"]
    style tau fill:#4fc3f7,stroke:#333,color:#000
    style alpha_synuclein fill:#4fc3f7,stroke:#333,color:#000
    style alpha_synuclein_1 fill:#4fc3f7,stroke:#333,color:#000
    style tau_2 fill:#4fc3f7,stroke:#333,color:#000
    style TDP_43 fill:#4fc3f7,stroke:#333,color:#000
    style tau_3 fill:#4fc3f7,stroke:#333,color:#000
    style TDP_43_4 fill:#4fc3f7,stroke:#333,color:#000
    style alpha_synuclein_5 fill:#4fc3f7,stroke:#333,color:#000
    style tau_6 fill:#4fc3f7,stroke:#333,color:#000
    style TDP_43_7 fill:#4fc3f7,stroke:#333,color:#000
    style tau_8 fill:#4fc3f7,stroke:#333,color:#000
    style alzheimers_disease fill:#ef5350,stroke:#333,color:#000
    style alpha_synuclein_9 fill:#4fc3f7,stroke:#333,color:#000
    style parkinsons_disease fill:#ef5350,stroke:#333,color:#000
    style TDP_43_10 fill:#4fc3f7,stroke:#333,color:#000
    style frontotemporal_dementia fill:#ef5350,stroke:#333,color:#000
    style tau_11 fill:#4fc3f7,stroke:#333,color:#000
    style frontotemporal_dementia_12 fill:#ef5350,stroke:#333,color:#000
    style alpha_synuclein_13 fill:#4fc3f7,stroke:#333,color:#000
    style lewy_body_dementia fill:#ef5350,stroke:#333,color:#000
    style cross_seeding fill:#ffd54f,stroke:#333,color:#000
    style multiple_system_atrophy fill:#ef5350,stroke:#333,color:#000
    style TGM2 fill:#ce93d8,stroke:#333,color:#000
    style transglutaminase_2 fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 TGM2 — PDB 1KV3 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Protein aggregation cross-seeding across neurodegenerative diseases

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Glycosaminoglycan Template Disruption Approach
Score: 0.60 · HSPG2
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58 · TREM2
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55 · G3BP1
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Score: 0.54 · DNAJB6
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.47 · PHB2
→ View all analysis hypotheses